Literature DB >> 36105008

A retrospective analysis of relapse-related factors for ovarian borderline tumors.

Dan Ye1, Haoran Shen1, Wu Huang1, Liangqing Yao1.   

Abstract

OBJECTIVES: Since patients with borderline ovarian tumors (BOTs) are relatively young with good survival rates, conservative surgery is prioritized as a therapeutic intervention. However, the high recurrence rate of this tumor remains an issue that demands further attention. In addition, it is unclear whether the increment of recurrent risk is attributed to conservative surgery or staging surgery. This study was designed to analyze the relapse-related factors of BOTs.
METHODS: This retrospective cohort study was comprised of 74 patients with BOTs who underwent surgery at the Obstetrics and Gynecology Hospital of Fudan University from September 2014 to September 2017. The recurrence-free survival (RFS) rate was calculated using the Kaplan-Meier method, while the risk factors of RFS were evaluated using Cox-regression analysis.
RESULTS: The 3-year RFS was 2.7% with a median follow-up duration of 45 months (range: 28-62). Kaplan-Meier analysis indicated that low tumor node metastasis (TNM) stage (P = 0.005), lymphadenectomy (P = 0.052) and fertility-preservation surgery (P = 0.059) were the factors that may lower recurrence. Meanwhile, Cox-regression showed that only low TNM stage was significantly associated with a better RFS (P = 0.005).
CONCLUSIONS: With the removal of visible lesions by standard surgery, patients at TNM stage I had a better RFS. Fertility-preservation surgery did not increase the recurrence risk. For bilateral ovarian cyst however, it was unclear whether bilateral cystectomy can increase the recurrence risk. Therefore, further study is required. AJTR
Copyright © 2022.

Entities:  

Keywords:  Borderline ovarian tumors; fertility-preservation surgery; recurrent-free survival; stage

Year:  2022        PMID: 36105008      PMCID: PMC9452353     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  22 in total

1.  The effect of hysterectomy on survival of patients with borderline ovarian tumors.

Authors:  Joseph Menczer; Angela Chetrit; Siegal Sadetzki
Journal:  Gynecol Oncol       Date:  2012-02-21       Impact factor: 5.482

2.  Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options.

Authors:  Emile Daraï; Raffaèle Fauvet; Catherine Uzan; Sébastien Gouy; Pierre Duvillard; Philippe Morice
Journal:  Hum Reprod Update       Date:  2012-12-12       Impact factor: 15.610

3.  Effect of surgical staging on 539 patients with borderline ovarian tumors: a Turkish Gynecologic Oncology Group study.

Authors:  Tevfik Guvenal; Polat Dursun; Pinar S Hasdemir; Merih Hanhan; Suleyman Guven; Hakan Yetimalar; Behice P Goksedef; Derya K Sakarya; Arzu Doruk; Mustafa C Terek; Bahadir Saatli; Kadir Guzin; Aydin Corakci; Emek Deger; Husnu Celik; Ahmet Cetin; Aydin Ozsaran; Ayşe Ozbakkaloglu; Ali Kolusari; Cetin Celik; Refik Keles; Fulya G Sagir; Saffet Dilek; Turhan Uslu; Yilmaz Dikmen; Ozden Altundag; Ali Ayhan
Journal:  Gynecol Oncol       Date:  2013-09-07       Impact factor: 5.482

4.  Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.

Authors:  Koji Matsuo; Hiroko Machida; Tsuyoshi Takiuchi; Brendan H Grubbs; Lynda D Roman; Anil K Sood; David M Gershenson
Journal:  Gynecol Oncol       Date:  2017-01-26       Impact factor: 5.482

5.  Impact of lymphadenectomy on survival after recurrence in patients with advanced ovarian cancer without suspected lymph node metastasis.

Authors:  E Sun Paik; Minhee Shim; Hyun Jin Choi; Yoo-Young Lee; Tae-Joong Kim; Jeong-Won Lee; Byoung-Gie Kim; Duk-Soo Bae; Chel Hun Choi
Journal:  Gynecol Oncol       Date:  2016-08-25       Impact factor: 5.482

Review 6.  Staging for low malignant potential ovarian tumors: a global perspective.

Authors:  Sherif A M Shazly; Shannon K Laughlin-Tommaso; Sean C Dowdy; Abimbola O Famuyide
Journal:  Am J Obstet Gynecol       Date:  2016-04-27       Impact factor: 8.661

7.  Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.

Authors:  Se Ik Kim; Eun Ji Lee; Maria Lee; Hyunhoon Chung; Jae-Weon Kim; Noh Hyun Park; Yong-Sang Song; Hee Seung Kim
Journal:  Int J Gynecol Cancer       Date:  2020-10-14       Impact factor: 3.437

Review 8.  Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment.

Authors:  María Guadalupe Patrono; Lucas Minig; Ivan Diaz-Padilla; Nuria Romero; Juan Francisco Rodriguez Moreno; Jesus Garcia-Donas
Journal:  Ecancermedicalscience       Date:  2013-12-17

9.  The impact of lymph node dissection on survival in patients with clinical early-stage ovarian cancer.

Authors:  Ting Deng; Qidan Huang; Ting Wan; Xiaoling Luo; Yanling Feng; He Huang; Jihong Liu
Journal:  J Gynecol Oncol       Date:  2021-05       Impact factor: 4.401

10.  Borderline ovarian tumors: clinical characteristics, management, and outcomes - a multicenter study.

Authors:  Mehmet Gokcu; Kemal Gungorduk; Osman Aşıcıoğlu; Nilüfer Çetinkaya; Tayfun Güngör; Gonca Pakay; Zeliha Fırat Cüylan; Tayfun Toptaş; Ramazan Özyurt; Elif Ağaçayak; Aykut Ozdemir; Onur Erol; Anıl Turan; Varol Gülseren; Mehmet Sait İcen; Taylan Şenol; Hakan Güraslan; Burcu Yücesoy; Ahmet Sahbaz; Ozgu Gungorduk; Berhan Besimoğlu; Kaan Pakay; Osman Temizkan; Muzaffer Sancı; Tayup Şimşek; Mehmet Mutlu Meydanlı; Mehmet Harma; Levent Yaşar; Birtan Boran; Aysel Derbent Uysal; Ateş Karateke
Journal:  J Ovarian Res       Date:  2016-10-18       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.